72 related articles for article (PubMed ID: 28076913)
1. The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics.
Patwardhan A
Cureus; 2020 Feb; 12(2):e7049. PubMed ID: 32128294
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin in the treatment of sporadic inclusion body myositis: time for new evidence?
Fontanelli L; Vadi G; Schirinzi E; Di Rauso G; Bellini G; Ricci G; Siciliano G
Clin Exp Rheumatol; 2024 Feb; 42(2):462-463. PubMed ID: 38372729
[No Abstract] [Full Text] [Related]
3. Long-term day-case treatment of peripheral neuromuscular disease with intravenous immunoglobulin: the practice of a regional day-case service in Preston, Lancashire.
Nixon J; McHugh C; Jones S
Clin Med (Lond); 2013 Aug; 13(4):358-61. PubMed ID: 23908504
[TBL] [Abstract][Full Text] [Related]
4. Considerations for dosing immunoglobulin in obese patients.
Hodkinson JP
Clin Exp Immunol; 2017 Jun; 188(3):353-362. PubMed ID: 28263379
[TBL] [Abstract][Full Text] [Related]
5. Trial of intravenous immunoglobulin in dermatomyositis: a critically appraised research paper.
Pandya R; Kleitsch J; Werth VP
Br J Dermatol; 2023 May; 188(6):738-739. PubMed ID: 36946215
[No Abstract] [Full Text] [Related]
6. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Aggarwal R; Rider LG; Ruperto N; Bayat N; Erman B; Feldman BM; Oddis CV; Amato AA; Chinoy H; Cooper RG; Dastmalchi M; Fiorentino D; Isenberg D; Katz JD; Mammen A; de Visser M; Ytterberg SR; Lundberg IE; Chung L; Danko K; García-De la Torre I; Song YW; Villa L; Rinaldi M; Rockette H; Lachenbruch PA; Miller FW; Vencovsky J;
Ann Rheum Dis; 2017 May; 76(5):792-801. PubMed ID: 28385805
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis.
Galimberti F; Kooistra L; Li Y; Chatterjee S; Fernandez AP
Clin Exp Dermatol; 2018 Dec; 43(8):906-912. PubMed ID: 29856076
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.
Mainetti C; Terziroli Beretta-Piccoli B; Selmi C
Clin Rev Allergy Immunol; 2017 Dec; 53(3):337-356. PubMed ID: 29090371
[TBL] [Abstract][Full Text] [Related]
9. Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study.
Chérin P; Pindi Sala T; Clerson P; Dokhan A; Fardini Y; Duracinsky M; Crave JC; Chassany O
Medicine (Baltimore); 2020 Feb; 99(7):e19012. PubMed ID: 32049796
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus.
Limaye VS; Lester S; Blumbergs P; Roberts-Thomson PJ
Int J Rheum Dis; 2010 May; 13(2):132-7. PubMed ID: 20536597
[TBL] [Abstract][Full Text] [Related]
11. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.
Gandiga PC; Ghetie D; Anderson E; Aggrawal R
Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663
[TBL] [Abstract][Full Text] [Related]
12. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
Foreman C; Russo P; Davies N; Hissaria P; Proudman S; Hughes T; Limaye V
Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913
[TBL] [Abstract][Full Text] [Related]
13. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).
Pongratz D
J Neurol; 2006 Sep; 253 Suppl 5():V64-5. PubMed ID: 16998756
[TBL] [Abstract][Full Text] [Related]
15. [Current therapy for polymyositis and dermatomyositis].
Chérin P
Rev Med Interne; 2008 Jun; 29 Spec No 2():9-14. PubMed ID: 18927983
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
